A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto)

Trial Profile

A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin; Pertuzumab; Trastuzumab
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms G7; GeparSepto
  • Most Recent Events

    • 05 Jun 2018 Results investigating the hypothsis that the individual patterns of mutational signatures determine the clinical behavior of breast cancer (BC) , in particular response to neoadjuvant chemotherapy presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 09 Dec 2017 Results assessing survival analysis presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 07 Dec 2017 According to a Celgene Corporation media release, The German Breast Group and Celgene Corporation announced -term invasive disease-free survival results at the 2017 San Antonio Breast Cancer Symposium (SABCS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top